{"id":849,"date":"2019-11-01T13:20:10","date_gmt":"2019-11-01T00:20:10","guid":{"rendered":"https:\/\/clladvocates.nz\/?p=849"},"modified":"2019-11-01T13:20:10","modified_gmt":"2019-11-01T00:20:10","slug":"ibrutinib-may-be-more-effective-than-ofatumumab-in-chronic-lymphocytic-leukemia","status":"publish","type":"post","link":"https:\/\/clladvocates.nz\/?p=849","title":{"rendered":"Ibrutinib May Be More Effective Than Ofatumumab in Chronic Lymphocytic Leukemia"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;3&#8243; bottom_padding=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243;][vc_column width=&#8221;1\/1&#8243;][vc_custom_heading heading_semantic=&#8221;h1&#8243; text_size=&#8221;h1&#8243;]Ibrutinib May Be More Effective Than Ofatumumab in Chronic Lymphocytic Leukemia[\/vc_custom_heading][vc_column_text]<a href=\"https:\/\/www.hematologyadvisor.com\/home\/topics\/leukemia\/long-term-safety-and-efficacy-analysis-of-resonate-trial-in-patients-with-cll-sll\/\" target=\"_blank\" rel=\"noopener noreferrer\">This article was originally published on Hematology Advisor<\/a><\/p>\n<p>Final results from the phase 3 RESONATE trial (ClinicalTrials.gov Identifier:<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01578707\" target=\"_blank\" rel=\"noreferrer noopener\" aria-label=\" (opens in a new tab)\">\u00a0NCT01578707<\/a>) suggest that ibrutinib may be more effective than ofatumumab for treating patients with relapsed or refractory\u00a0<a href=\"https:\/\/www.hematologyadvisor.com\/home\/topics\/leukemia\/risk-factors-for-developing-second-primary-malignancy-with-history-of-chronic-lymphocytic-leukemia\/\">chronic lymphocytic leukemia (CLL)<\/a>. The results were published in the\u00a0<em>American Journal of Hematology<\/em>.<\/p>\n<p>Earlier results from RESONATE suggested that single-agent ibrutinib, a Bruton\u2019s tyrosine kinase inhibitor administered once daily, has greater efficacy compared with ofatumumab for treating patients with CLL\/small lymphocytic lymphoma, including those with high-risk features such as 17p deletion,\u00a0<em>TP53<\/em>\u00a0mutation, 11q deletion, or unmutated\u00a0<em>IGHV<\/em>. For this analysis, the authors reviewed long-term safety and efficacy data.<\/p>\n<p>A total of 195 patients were randomly assigned to receive ibrutinib and 196 received ofatumumab. The median duration of treatment was 41 months (range, 0.2-71.1) with ibrutinib and 5.3 months (range, 0-9.0) with ofatumumab; the planned duration with the latter, however, was 24 weeks. Of the 196 patients receiving ofatumumab, 68% (133) crossed over to the ibrutinib treatment arm.<\/p>\n<p>Median overall follow-up was 74 months. Median progression-free survival (PFS) was 44.1 months with ibrutinib and 8.1 months with ofatumumab (hazard ratio [HR], 0.148;\u00a0<em>P\u00a0<\/em>&lt;.001). PFS was also better in the high-risk patient group that received ibrutinib compared with high-risk patients who received ofatumumab (HR, 0.110).<\/p>\n<p>Overall survival was better in the ibrutinib group (67.7 vs 65.1 months), even after adjusting for crossover (HR, 0.639).<\/p>\n<p>Frequently reported grade 3 or worse adverse events in the ibrutinib group included neutropenia (25%), pneumonia (21%), thrombocytopenia (10%), anemia (9%), hypertension (9%), urinary tract infection (7%), diarrhea (7%), and atrial fibrillation (6%). The prevalence of grade 3 or worse adverse events in patients receiving ibrutinib was 62% in the first year of treatment and decreased to 32% by the sixth year of treatment.<\/p>\n<p>At study termination, 36.9% of patients who received ibrutinib discontinued treatment due to progressive disease, 16.4% due to adverse events, 7.7% due to withdrawal from study, 6.7% due to death, 10.3% due to investigator decision, and 22.1% due to study termination by sponsor. Of the 133 patients who crossed over from the ofatumumab group, 47 were still receiving therapy at study closure.<\/p>\n<p>\u201cThese 6-year follow-up results from the RESONATE study confirm the robust and durable efficacy of ibrutinib with extended treatment in patients with relapsed or refractory CLL,\u201d the researchers wrote.<\/p>\n<p><strong>Reference<\/strong><\/p>\n<p>1. \u00a0 \u00a0 Munir T, Brown JR, O\u2019Brien S, et al.<a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/ajh.25638\" target=\"_blank\" rel=\"noreferrer noopener\" aria-label=\" (opens in a new tab)\">\u00a0Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma<\/a>\u00a0[published online September 11, 2019].\u00a0<em>Am J Hematol<\/em>.<em>\u00a0<\/em>doi:10.1002\/ajh.25638[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Final results from the phase 3 RESONATE trial (ClinicalTrials.gov Identifier: NCT01578707) suggest that ibrutinib may be more effective than ofatumumab for treating patients with relapsed or refractory chronic lymphocytic leukemia (CLL). The results were published in the American Journal of Hematology.<\/p>\n","protected":false},"author":1,"featured_media":850,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12],"tags":[],"class_list":["post-849","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-media"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2019\/11\/doctorsreviewingdataondigi_1498434-860x573.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=849"}],"version-history":[{"count":1,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/849\/revisions"}],"predecessor-version":[{"id":851,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/849\/revisions\/851"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/850"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}